Related Experiment Videos
Single-agent docetaxel (Taxotere) in randomized phase III trials
1Department of Drug Development, Sarah Cannon Cancer Center, Nashville, TN 37203, USA.
Seminars in Oncology
|July 30, 1999
Summary
Single-agent docetaxel demonstrated superior response rates and improved survival in metastatic breast cancer patients previously treated with anthracyclines. It is now the preferred therapy over combination regimens in this setting.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Trials
Background:
- Metastatic breast cancer (MBC) treatment lacks standard options for patients progressing on anthracyclines.
- Limited phase III trial data existed for this specific patient population.
Purpose of the Study:
- To evaluate the efficacy of single-agent docetaxel versus combination chemotherapy in anthracycline-pretreated MBC patients.
- To establish docetaxel as a preferred treatment option in this setting.
Main Methods:
- Review of three randomized phase III clinical trials comparing single-agent docetaxel (100 mg/m2 every 3 weeks) to combination chemotherapy regimens.
- Patient population included metastatic breast cancer patients pretreated with anthracycline-based chemotherapy.
Main Results:
- Single-agent docetaxel achieved overall response rates of 30-42%, exceeding those of combination regimens in all trials.
- One trial showed significantly improved overall survival for docetaxel-treated patients.
- Docetaxel demonstrated continued antitumor activity and lack of anthracycline cross-resistance.
Conclusions:
- Docetaxel is the preferred therapy over specific combination regimens (mitomycin C/vinblastine, methotrexate/5-FU, 5-FU/vinorelbine) for anthracycline-resistant/pretreated MBC.
- Results confirm docetaxel's efficacy in anthracycline-exposed patients.
- A fourth trial suggests docetaxel combined with doxorubicin may be highly effective.